After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Most recently, Yahoo Finance reported about the stock as it publicized that Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Kymera Therapeutics Inc is $2.58B. A total of 0.74 million shares were traded on the day, compared to an average of 876.17K shares.
In the most recent transaction, Booth Bruce sold 139,255 shares of KYMR for 42.23 per share on Mar 13 ’24. After the transaction, the Director now owns 828,830 company shares. In a previous transaction on Mar 13 ’24, Atlas Venture Fund X, L.P. sold 115,090 shares at 42.23 per share. KYMR shares that 10% Owner owns now total 4,676,075.
Among the insiders who sold shares, Atlas Venture Fund X, L.P. disposed of 24,165 shares on Mar 13 ’24 at a per-share price of $42.23. This resulted in the 10% Owner holding 828,830 shares of KYMR after the transaction. In another insider transaction, Booth Bruce sold 162,918 shares at $41.98 per share on Mar 12 ’24. Company shares held by the Director now total 852,995.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, KYMR has a high of $45.31 and a low of $9.60.
As of this writing, KYMR has an earnings estimate of -$0.72 per share for the current quarter. EPS was calculated based on a consensus of 12 estimates, with a high estimate of -$0.57 per share and a lower estimate of -$0.87. The company reported an EPS of -$0.9 in the last quarter, which was -40.60% lower than expectations of -$0.64.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. KYMR’s latest balance sheet shows that the firm has $442.42M in Cash & Short Term Investments as of fiscal 2021. There were $17.96M in debt and $92.54M in liabilities at the time. Its Book Value Per Share was $7.11, while its Total Shareholder’s Equity was $459.64M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for KYMR is Buy with a score of 4.20.
